Jiachen Xu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Nature communications

Journal for immunotherapy of cancer

Thoracic cancer

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Jiefei Han, Yiting Dong, Xiuli Zhu, Alexandre Reuben, Jianjun Zhang, Jiachen Xu, Hua Bai, Jianchun Duan, Rui Wan, Jie Zhao, Jing Bai, Xuefeng Xia, Xin Yi, Chao Cheng, Jie Wang, Zhijie Wang
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15 (1) (2024)
Xiang Li, Yangzhong Zhou, Bing Xu, Yunhe Qin, Jiuliang Zhao, Mengtao Li, Jiachen Xu, Guanqiao Li
Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for immunotherapy of cancer 12 (1) (2024)
Chao Wang, Kailun Fei, Lihui Liu, Jianchun Daun, Zhijie Wang, Sini Li, Jiachen Xu, Xue Zhang, Yanhua Tian, Yan Qu, Hua Bai, Jie Wang
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment. Thoracic cancer (2023)
Boyang Sun, Tian Qiu, Xiaoling Zeng, Jianchun Duan, Hua Bai, Jiachen Xu, Jin Li, Jun-Ling Li, Xuezhi Hao, Yutao Liu, Lin Lin, Hongyu Wang, Xin Zhang, Jia Zhong, Jie Wang, Jianming Ying, Zhijie Wang
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors. Cancer research communications 3 (4) (2023)
Yue Peng, Bin Qiu, Fengwei Tan, Jiachen Xu, Fenglong Bie, Huayu He, Lei Liu, He Tian, Guangyu Bai, Bolun Zhou, Yuan Li, Qilin Huai, Zhenlin Yang, Shugeng Gao
TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. Thoracic cancer 13 (14) (2022)
Jun Du, Yundi Zhang, Yiting Dong, Jianchun Daun, Hua Bai, Jie Wang, Jiachen Xu, Zhijie Wang
Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. Thoracic cancer 12 (20) (2021)
Jiefei Han, Ruofei Yu, Jianchun Duan, Jin Li, Wei Zhao, Guoshuang Feng, Hua Bai, Yu-Qi Wang, Xue Zhang, Rui Wan, Jiachen Xu, Xin Wang, Yanfang Guan, Xuefeng Xia, Zhuoran Yao, Kailun Fei, David P Carbone, Zhijie Wang, Jie Wang
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. Science advances 7 (21) (2021)